Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors

Founded by pioneers of targeted oncology, Theseus is developing best-in-class TKIs to overcome cancer resistance Presentation at AACR highlights THE-630, the Company's next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST) BO... Biopharmaceuticals, Oncology, Venture Capital Theseus Pharmaceuticals, targeted oncology
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news